Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

Abrams P: New words for old: lower urinary tract symptoms for “prostatism”. BMJ 1994, 308:929–930.

Roehrborn CG: Reducing the risk of benign prostatic hyperplasia progression. Rev Urol 2002, 5:29–38.

Guess HA: Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 1995, 22:247–261.

Thorpe A, Neal D: Benign prostatic hyperplasia. Lancet 2003, 361:1359–1367.

Chiricos TN, Sanford E: Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia. J Urol 1996, 155:1311–1316.

Jacobsen SJ, Guess HA, Panser L, et al.: A population-based study of health care-seeking behavior for treatment of urinary symptoms. Arch Fam Med 1993, 2:729–735.

Abrams P, Cardozo L, Fall M, et al.: The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Neururol Urodyn 2002, 21:167–178.

Caine M, Raz S, Zeigler M: Adrenergic and cholinergic receptors in the human prostate, prostatic capsule, and bladder neck. Br J Urol 1975, 47:193–202.

Rasmusson GH, Reynolds GF, Utre T, et al.: Azasteroids as inhibitors of rat 5-alpha reductase. J Med Chem 1984, 27:1690–1701.

Kirby RS, Vale J, Bryan J, et al.: Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study. Eur Urol 1993, 24:20–26.

Andersen, JT, Ekman P, Wolf H, et al.: Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 1995, 46:631–637.

McVary KT: A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther 2007, 29:387–398.

Drescher P, Eckert RE, Madsen PO: Smooth muscle contractility in prostatic hyperplasia: rote of cyclic adenosine monophosphate. Prostate 1994, 25:76–80.

Loughney K, Hill TR, Florio VA, et al.: Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase. Gene 1998, 216:139–147.

Yanaka N, Kotera J, Ohtsuka A, et al.: Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. Eur J Biochem 1998, 255:391–393.

Stacey P, Rulten S, Dapling A, Phillips SC: Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5). Biochem Biophys Res Commun 1998, 247:249–254.

Ueckert S, Kuethe A, Jonas U, et al.: Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001, 166:2484–2490.

Ueckert S, Oelke M, Stief CG, et al.: Immunohistochemical distribution of cAMP-and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 2006, 49:740–745.

Stief CG, Porst H, Ulbrich E: Vardenafil in the treatment of symptomatic benign prostatic hyperplasia [abstract]. J Urol 2007, 177(Suppl):517.

McVary KT, Roehrborn CG, Kaminetsky JC, et al.: Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007, 177:1401–1407.

McVary KT, Monnig W, Camps JL, et al.: Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007, 177:1071–1077.

Guh JH, Hwang TL, Ko FN, et al.: Antiproliferative effect in human prostatic smooth muscle cells by nitric oxide donor. Mol Pharmacol 1998, 53:467–474.

Adolfsson PI, Ahlstrand C, Varenhorst E, et al.: Lysophosphatidic acid stimulates proliferation of cultured smooth muscle cells from human BPH tissue: sildenafil and papaverin generate inhibition. Prostate 2002, 51:50–58.

Cook AL, Haynes JM: Protein kinase G II-mediated proliferative effects in human cultured prostatic stromal cells. Cell Signal 2004, 16:253–261.

Tinel H, Stelte-Ludwig B, Hüetter J, Sandor P: Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006, 96:1259–1263.

Truss MC, Ueckert S, Stief CG, et al.: Porcine detrusor cyclic nucleotide phosphodiesterase isoenzymes: characterization and functional effects of various phosphodiesterase inhibitors in vitro. Urology 1995, 45:893–901.

Truss MC, Ueckert S, Stief CG, et al.: Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. Identification and characterization. Urol Res 1996, 24:123–128.

Truss MC, Ueckert S, Stief CG, et al.: Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. Effects of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro. Urol Res 1996, 24:129–134.

Qiu Y, Kraft P, Craig EC, et al.: Identification and functional study of phosphodiesterases in rat urinary bladder. Urol Res 2001, 29:388–392.

Qui Y, Kraft P, Craig EC, et al.: Cyclic nucleotide phosphodiesterases in rabbit detrusor smooth muscle. Urology 2002, 59:145–149.

Filippi S, Morelli AM, Sandner P, et al.: Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007, 148:1019–1029.

Gu B, Reiter JP, Schwinn DA, et al.: Effects of alpha 1-adrenergic receptor subtype selective antagonists on lower urinary tract function in rats with bladder outlet obstruction. J Urol 2004, 172:758–762.

Conners W, Whitebeck C, Chicester P, et al.: L-NAME, a nitric oxide synthase inhibitor, diminishes oxidative damage in urinary bladder partial outlet obstruction. Am J Physiol 2005, 290:357–363.

Matsumoto S, Watanabe E, Nakata Y, et al.: Bladder protective effects of PDE5 inhibition: efficacy of vardenafil on rat bladder with outlet obstruction. J Urol 2007, 177:446.

Beamon C, Salkini M, Mazur C, et al.: The effect of sildenafil citrate on bladder outlet obstruction in a mouse model. J Urol 2007, 177:140.

Gacci M, Del Popolo G, Macchiarella A, et al.: Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 2007, 178:2040–2043.

Porst H, Sharlip ID, Hatzichristou D, et al.: Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: a randomized, double-blind, placebo-controlled study. Eur Urol 2006, 50:1086–1095.

Porst H, Lungimayr G, Deutsch-Öesterreichische STEADY-Studiengruppe: Efficacy and tolerability of vardenafil within the time window of 6 hours after administration and beyond. MMW-Fortschr Med Originalien 2005, 50:27–32.

Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al.: Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003, 169:2253–2256.

Lee KS, Choo MS, Kim DY, et al.: Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 2005, 174:1334–1338.

Kaplan SA, Walmsley K, Te AE: Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005, 174:2273–2276.

Abrams P, Kaplan SA, De Koning Gans HJ, Millard R: Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006, 175:999–1004.

Harrison SC, Hunnam GR, Farman P, et al.: Bladder instability and denervation in patients with bladder outflow obstruction. Br J Urol 1987, 60:519–522.

Mirone V, Imbimbo C, Sessa G, et al.: Correlation between detrusor collagen content and urinary symptoms in patients with prostatic obstruction. J Urol 2004, 172:1386–1389.

Laschke S, Carl S: Detrusor overactivity after prostate resection-preventing postoperative incontinence with darifenacin. 29th Congress Societé Internationale d’Urologie, Paris, France, September 2–6, 2007. Urology 2007, 70:254.

Nordling J: Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 2005, 95:1006–1012.

Roehrborn CG, Van Kerrebroeck P, Nordling J: Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003, 92:257–261.

Costabile RA, Steers WD: How can we best characterize the relationship between erectile dysfunction and benign prostatic hyperplasia? J Sex Med 2006, 3:676–681.

Sak SC, Hussain C, Johnston C, et al.: What is the relationship between male sexual function and lower urinary tract symptoms (LUTS). Eur Urol 2004, 46:482–487.